title: A homogenous luminescence assay reveals novel inhibitors for giardia lamblia carbamate kinase.
abstract: The human pathogen Giardia lamblia is an anaerobic protozoan parasite that causes giardiasis, one of the most common diarrheal diseases worldwide. Although several drugs are available for the treatment of giardisis, resistance to these drugs has been reported and is likely to increase. The Giardia carbamate kinase (glCK) plays an essential role in Giardia metabolism and has no homologs in humans, making it an attractive candidate for anti-Giardia drug development. We have developed a luminescent enzyme coupled assay to measure the activity of glCK by quantitating the amount of ATP produced by the enzyme. This assay is homogeneous and has been miniaturized into a 1536-well plate format. A pilot screen against 4,096 known compounds using this assay yielded a signal-to-basal ratio of 11.5 fold and Z' factor of 0.8 with a hit rate of 0.9 % of inhibitors of glCK. Therefore, this Giardia lamblia carbamate kinase assay is useful for high throughput screening of large compound collection for identification of the inhibitors for drug development.
authors: National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA.
authors: Catherine Z
authors: CZ
authors: Chen
authors: Noel
authors: N
authors: Southall
authors: Andrey
authors: A
authors: Galkin
authors: Kap
authors: K
authors: Lim
authors: Juan J
authors: JJ
authors: Marugan
authors: Liudmila
authors: L
authors: Kulakova
authors: Paul
authors: P
authors: Shinn
authors: Danielle
authors: D
authors: van Leer
authors: Wei
authors: W
authors: Zheng
authors: Osnat
authors: O
authors: Herzberg
keywords: Carbamate kinase; Giardia; assay development.; high throughput screening
references: J Biomol Screen. 1999;4(2):67-73
references: 10838414
references: Expert Opin Drug Saf. 2003 Nov;2(6):529-41
references: 14585063
references: J Biomol Screen. 2008 Aug;13(7):609-18
references: 18591513
references: Trends Parasitol. 2003 Jan;19(1):9-12
references: 12488215
references: J Bacteriol. 1982 Jun;150(3):1024-32
references: 6281231
references: Antimicrob Agents Chemother. 2001 Jun;45(6):1810-4
references: 11353630
references: Antimicrob Agents Chemother. 2011 Feb;55(2):667-75
references: 21078930
references: Int J Parasitol. 1990 Jul;20(4):489-96
references: 2210942
references: Eur J Biochem. 1998 Apr 1;253(1):280-91
references: 9578487
references: Biochim Biophys Acta. 1964 Dec 23;92:498-512
references: 14264883
references: JALA Charlottesv Va. 2008 Apr;13(2):79-89
references: 18496600
references: Int J Parasitol. 1995 May;25(5):593-9
references: 7635637
references: Mol Biochem Parasitol. 1992 Jul;53(1-2):97-103
references: 1501649
references: Appl Environ Microbiol. 1995 Jan;61(1):310-6
references: 16534912
references: Mol Biochem Parasitol. 1996 Jun;78(1-2):117-25
references: 8813682
references: Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010 Apr 1;66(Pt 4):386-90
references: 20383005
references: PLoS One. 2009 Sep 24;4(9):e7150
references: 19777064
references: Mol Biochem Parasitol. 1992 Mar;51(1):29-36
references: 1314332
references: Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11473-8
references: 16864780
references: Sci Transl Med. 2011 Apr 27;3(80):80ps16
references: 21525397
references: J Infect Dis. 2003 Jun 15;187(12):1849-59
references: 12792861
references: Antimicrob Agents Chemother. 1998 Jun;42(6):1488-92
references: 9624499